Contents

Glossary

• 1.7 Procedural matters
  • 1.7.1 Operations/policies of the Committee
    • 1.7.1.2 Sponsor access to evaluation reports
• 1.8 NDPSC working parties
  • 1.8.1 Trans-Tasman Harmonisation Working Party (Medicines)
    • 1.8.1.1 Minutes from TTHWP 13th Meeting
    • 1.8.1.2 Matters arising from the 13th Meeting
    • 1.8.1.3 Matters arising from NDPSC Consideration of TTHWP Items
      • 1.8.1.3.1 Amphotericin
      • 1.8.1.3.2 Nicotine
      • 1.8.1.3.3 Hyoscine and Hyoscyamine
      • 1.8.1.3.4 Consideration of Scheduling of Substances where there are no Schedule 2 or Schedule 3 Products in the Marketplace
      • 1.8.1.3.5 Consideration of Scheduling of Substances used in the Treatment of Tinea Pedis
      • 1.8.1.3.6 Consideration of Amendments to Scheduling to achieve Harmonisation with New Zealand

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.1 SUSDP, Part 1
  • 2.1.1 Interpretation - "Dermal Use", "Topical Use" and "External"
  • 2.1.2 Definition of 'Child Resistance' and Storage Statements for Schedule 5 and Schedule 6 Products

Top of page

Agricultural/Veterinary, Industrial and Domestic Chemicals

4. Other outstanding matters from previous meetings

• 4.1 Alkaline salts
• 4.2 Thiabendazole
• 4.3 Eyelash and eyebrow tinting products
• 4.4 Pine oils
• 4.5 Glycolic acid
• 4.6 Carbamide peroxide/hydrogen peroxide

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 5.1 SUSDP, Part 4
  • 5.1.1 Potassium azeloyl diglycinate
  • 5.1.2 Sodium polystyrene sulphonate

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

• 6.1 Emodepside and praziquantel
• 6.2 Milbemectin
• 6.3 Pinoxaden
• 6.4 Prothioconazole
• 6.5 Imidapril
• 6.6 Aminopyralid
• 6.7 Halofuginone
• 6.8 Paraquat
• 6.9 Dichlobenil
• 6.10 Spinosad
• 6.11 Tributyltin Oxide (TBTO) and Triclosan
• 6.12 N-tallow-1, 3-propanediamine diacetate & tallow alkylamine acetates
• 6.13 Aquarium chemicals (malachite gree, acriflavine, methylene blue, quinine, aminacrine)

Top of page

Pharmaceuticals

13. Other outstanding matters from previous meetings

• 13.1 Pseudoephedrine
• 13.2 Compounded codeine in XXXXXXXX

14. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 14.1 SUSDP, Part 4
  • 14.1.2 Sumatriptan
  • 14.1.3 Required advisory statements for medicine labels
  • 14.1.4 Pantroprazole
• 14.2 SUSDP, Part 5
  • 14.2.1.1 Orlistat
  • 14.2.1.2 Diphenhydramine
  • 14.2.2 Appendix K
    • 14.2.2.1 Amisulpride
    • 14.2.2.2 Clozapine
    • 14.2.2.3 Quetiapine
  • 14.2.3 Appendix A
    • 14.2.3.1 Blood Products

15. Matters referred by the Australian Drug Evaluation Committee (ADEC)

• 15.1 New substances (not seen before by the NDPSC)
  • 15.1.1 Laronidase - RCH
  • 15.1.2 Articaine
  • 15.1.3 Darifenacin hydrobromide
  • 15.1.4 Everolimus
  • 15.1.5 Octocog alfa
  • 15.1.6 Bevacizumab
  • 15.1.7 Cetuximab
  • 15.1.8 Cinacalcet
  • 15.1.9 Norelgestromin
  • 15.1.10 Poractant alfa
  • 15.1.11 Pregabalin

23. Amendments to the SUSDP

• 23.1.1 For information - minor editorial changes and errata in SUSDP 20